JAK1 and neoplasm: It is well established that indel mutations contribute to the generation of neoantigens, which increase tumor immunogenicity and the likelihood of response to ICB.17 However, more indels also increase the likelihood that important genes, such as JAK1 and B2M, that are necessary for effective antitumor immune response may become truncated and thereby contribute to resistance to ICB.